Comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions"

Pharmaceutical Research

Volumn 30, Issue 6, 2013, Pages 1467-1468

  Neuhoff, Sibylle ^a   Tucker, Geoff T ^b  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GEMFIBROZIL; INTERLEUKIN 6; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 1; PRAVASTATIN; PROTEIN OATP1B1; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

DRUG DISPOSITION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME KINETICS; HEPATOBILIARY SYSTEM; HUMAN; LETTER; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

FEMALE; HEPATOCYTES; HUMANS; LIVER; MALE; PRAVASTATIN;

EID: 84877753588     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-0988-5     Document Type: Letter

References (16)

1. Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, Bergman A. Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res. 2012;29(10):2860-73.
2. Li N, Zhang Y, Hua F, Lai Y. Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human. Drug Metab Dispos. 2009;37(1):66-73.
3. Li N, Bi YA, Duignan DB, Lai Y. Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes. Mol Pharm. 2009;6(4):1180-9.
4. Amundsen R, Christensen H, Zabihyan B, Asberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metab Dispos. 2010;38(9):1499-504.
5. Shitara Y, Takeuchi K, Nagamatsu Y, Wada S, Sugiyama Y, Horie T. Long-lasting inhibitory effects of cyclosporin A, but not tacrolimus, on OATP1B1- and OATP1B3-mediated uptake. Drug Metab Pharmacokinet. 2012 Jan 13.
6. Rowland-Yeo K, Jamei M, Aarabi M, Rostami-Hodjegan A. Application of physiologically based pharmacokinetic (PBPK) modeling for prediction of complex drug-drug interactions (DDIs) involving OATP1B1-mediated uptake and cytochrome P450 (CYP) metabolism and multiple inhibitors. Clin Pharmacol Ther. 2012;91:S47-8.
7. Abdallah AN, Billes MA, Attia Y, Doutremepuich C, Cassaigne A, Iron A. Evaluation of plasma levels of tumour necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy. Eur Heart J. 1997;18(6):1024-9.
8. Fardel O, Le Vee M. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Expert Opin Drug Metab Toxicol. 2009;5(12):1469-81.
9. Vee ML, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos. 2009;37(3):685-93.
10. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001;86(3):1154-9.
11. Perez-Villa F, Benito B, Llancaqueo M, Cuppoletti A, Roig E. Elevated levels of serum interleukin-6 are associated with low grade cellular rejection in patients with heart transplantation. Transplant Proc. 2006;38(9):3012-5.
12. Schaefer O, Ohtsuki S, Kawakami H, Inoue T, Liehner S, Saito A, et al. Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metab Dispos. 2012;40(1):93-103.
13. Jigorel E, Le Vee M, Boursier-Neyret C, Parmentier Y, Fardel O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006;34(10):1756-63.
14. Sahi J, Sinz MW, Campbell S, Mireles R, Zheng X, Rose KA, et al. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. Chem Biol Interact. 2006;159(2):156-68.
15. Giessmann T, Modess C, Hecker U, Zschiesche M, Dazert P, Kunert-Keil C, et al. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects. Clin Pharmacol Ther. 2004;75(3):213-22.
16. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, et al. The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol. 2000;157(5):1575-80.